Earlier this year, Bayer formed a new business unit that promised to shake up the consumer health category with a new personalised approach driven by digital technologies.
Regeneron and Bayer's efforts to defend their lucrative eye disease therapy Eylea from competition have been boosted by FDA approval of a new high-dose formulation of the
Bayer revealed in its second-quarter results update this morning that it has stopped the development of adrenomedullin pegol (PEG-ADM), which had reached phase 2 for the t
More than 1.5 billion people around the world are infected with soil-transmitted helminths (STHs), parasitic worms that damage their health and are a leading cause of maln
Personalised and precision health is a firmly established concept in the development of new prescription medicines, but not so much in the consumer health category.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.